Tcr2 Therapeutics Inc

-0.06 (-4.66%)
Products, Regulatory

TCR2 Therapeutics Announces Positive Topline Results From Phase 1 Portion Of Gavo-Cel Phase 1/2 Clinical Trial For Mesothelin-Expressing Solid Tumors

Published: 09/28/2022 10:57 GMT
Tcr2 Therapeutics Inc (TCRR) - Gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors With Additional Recist Reponses in Ovarian Cancer and Mesothelioma.
Tcr2 Therapeutics Inc - Phase 2 Portion of Trial Underway Implementing Multiple Approaches to Further Improve Clinical Outcomes.
Tcr2 Therapeutics Inc - Second Recist Partial Response in Ovarian Cancer Supports Broad Potential of Gavo-cel.
Tcr2 Therapeutics Inc - Positive Topline Results From Phase 1 Portion of Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-expressing Solid Tumors.